These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 19926405)
1. Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study. Grebely J; Petoumenos K; Matthews GV; Haber P; Marks P; Lloyd AR; Kaldor JM; Dore GJ; Hellard M; Drug Alcohol Depend; 2010 Mar; 107(2-3):244-9. PubMed ID: 19926405 [TBL] [Abstract][Full Text] [Related]
2. Recruitment and follow-up of injecting drug users in the setting of early hepatitis C treatment: insights from the ATAHC study. Nguyen OK; Dore GJ; Kaldor JM; Hellard ME; Int J Drug Policy; 2007 Oct; 18(5):447-51. PubMed ID: 17854736 [TBL] [Abstract][Full Text] [Related]
3. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Dore GJ; Hellard M; Matthews GV; Grebely J; Haber PS; Petoumenos K; Yeung B; Marks P; van Beek I; McCaughan G; White P; French R; Rawlinson W; Lloyd AR; Kaldor JM; Gastroenterology; 2010 Jan; 138(1):123-35.e1-2. PubMed ID: 19782085 [TBL] [Abstract][Full Text] [Related]
4. Reinfection with hepatitis C virus following sustained virological response in injection drug users. Grebely J; Knight E; Ngai T; Genoway KA; Raffa JD; Storms M; Gallagher L; Krajden M; Dore GJ; Duncan F; Conway B J Gastroenterol Hepatol; 2010 Jul; 25(7):1281-4. PubMed ID: 20594256 [TBL] [Abstract][Full Text] [Related]
5. Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users. Grebely J; Matthews GV; Hellard M; Shaw D; van Beek I; Petoumenos K; Alavi M; Yeung B; Haber PS; Lloyd AR; Kaldor JM; Dore GJ; J Hepatol; 2011 Jul; 55(1):76-85. PubMed ID: 21145855 [TBL] [Abstract][Full Text] [Related]
6. Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C. Alavi M; Spelman T; Matthews GV; Haber PS; Day C; van Beek I; Walsh N; Yeung B; Bruneau J; Petoumenos K; Dolan K; Kaldor JM; Dore GJ; Hellard M; Grebely J; Int J Drug Policy; 2015 Oct; 26(10):976-83. PubMed ID: 26115881 [TBL] [Abstract][Full Text] [Related]
7. Hepatitis C Treatment Uptake among Patients Who Have Received Opioid Substitution Treatment: A Population-Based Study. Midgard H; Bramness JG; Skurtveit S; Haukeland JW; Dalgard O PLoS One; 2016; 11(11):e0166451. PubMed ID: 27846264 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study. Grebely J; Dalgard O; Cunningham EB; Hajarizadeh B; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G; Swan T; Amin J; Marks PS; Quiene S; Applegate TL; Weltman M; Shaw D; Dunlop A; Hellard M; Bruneau J; Midgard H; Bourgeois S; Staehelin C; Dore GJ; Int J Drug Policy; 2017 Sep; 47():177-186. PubMed ID: 28624134 [TBL] [Abstract][Full Text] [Related]
9. Effect of pegylated interferon-α-2a treatment on mental health during recent hepatitis C virus infection. Alavi M; Grebely J; Matthews GV; Petoumenos K; Yeung B; Day C; Lloyd AR; Van Beek I; Kaldor JM; Hellard M; Dore GJ; Haber PS; J Gastroenterol Hepatol; 2012 May; 27(5):957-65. PubMed ID: 22142332 [TBL] [Abstract][Full Text] [Related]
10. Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study. Bajis S; Grebely J; Hajarizadeh B; Applegate T; Marshall AD; Ellen Harrod M; Byrne J; Bath N; Read P; Edwards M; Gorton C; Hayllar J; Cock V; Peterson S; Thomson C; Weltman M; Jefferies M; Wood W; Haber P; Ezard N; Martinello M; Maher L; Dore GJ; J Viral Hepat; 2020 Mar; 27(3):281-293. PubMed ID: 31698545 [TBL] [Abstract][Full Text] [Related]
11. Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study. Midgard H; Hajarizadeh B; Cunningham EB; Conway B; Backmund M; Bruggmann P; Bruneau J; Bourgeois S; Dunlop A; Foster GR; Hellard M; Robaeys G; Thurnheer MC; Weltman M; Amin J; Marks PS; Quiene S; Dore GJ; Dalgard O; Grebely J; Int J Drug Policy; 2017 Sep; 47():230-238. PubMed ID: 28633998 [TBL] [Abstract][Full Text] [Related]
12. Can Hepatitis C virus treatment be used as a prevention strategy? Additional model projections for Australia and elsewhere. Vickerman P; Martin N; Hickman M Drug Alcohol Depend; 2011 Jan; 113(2-3):83-5; discussion 86-7. PubMed ID: 20832198 [TBL] [Abstract][Full Text] [Related]
13. Peginterferon plus Ribavirin for chronic hepatitis C in opiate addicts on methadone/buprenorphine maintenance therapy. Belfiori B; Ciliegi P; Chiodera A; Bacosi D; Tosti A; Baldelli F; Francisci D Dig Liver Dis; 2009 Apr; 41(4):303-7. PubMed ID: 18938116 [TBL] [Abstract][Full Text] [Related]
14. Epidemiology, clinical data, and treatment of viral hepatitis in a large cohort of intravenous drug users. Gigi E; Sinakos E; Sykja A; Androulakis G; Tanis C; Stayridou V; Tsirogianni E; Zouridakis K; Bellou AL; Orfanou E; Raptopoulou-Gigi M J Addict Med; 2013; 7(1):52-7. PubMed ID: 23340710 [TBL] [Abstract][Full Text] [Related]
15. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. Grebely J; Genoway K; Khara M; Duncan F; Viljoen M; Elliott D; Raffa JD; DeVlaming S; Conway B Int J Drug Policy; 2007 Oct; 18(5):437-43. PubMed ID: 17854734 [TBL] [Abstract][Full Text] [Related]
16. Quality of Life and Social Functioning during Treatment of Recent Hepatitis C Infection: A Multi-Centre Prospective Cohort. Doyle JS; Grebely J; Spelman T; Alavi M; Matthews GV; Thompson AJ; Dore GJ; Hellard ME; PLoS One; 2016; 11(6):e0150655. PubMed ID: 27355323 [TBL] [Abstract][Full Text] [Related]
17. Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study. Cunningham EB; Hajarizadeh B; Dalgard O; Amin J; Hellard M; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G; Swan T; Marks PS; Quiene S; Applegate TL; Weltman M; Shaw D; Dunlop A; Bruneau J; Midgard H; Bourgeois S; Thurnheer MC; Dore GJ; Grebely J; BMC Infect Dis; 2017 Jun; 17(1):420. PubMed ID: 28610605 [TBL] [Abstract][Full Text] [Related]
18. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Poordad F; Bronowicki JP; Gordon SC; Zeuzem S; Jacobson IM; Sulkowski MS; Poynard T; Morgan TR; Molony C; Pedicone LD; Sings HL; Burroughs MH; Sniukiene V; Boparai N; Goteti VS; Brass CA; Albrecht JK; Bacon BR; Gastroenterology; 2012 Sep; 143(3):608-618.e5. PubMed ID: 22626609 [TBL] [Abstract][Full Text] [Related]
19. Integrated internist - addiction medicine - hepatology model for hepatitis C management for individuals on methadone maintenance. Martinez AD; Dimova R; Marks KM; Beeder AB; Zeremski M; Kreek MJ; Talal AH J Viral Hepat; 2012 Jan; 19(1):47-54. PubMed ID: 21129131 [TBL] [Abstract][Full Text] [Related]
20. Trends and factors in human immunodeficiency virus and/or hepatitis C virus testing and infection among injection drug users newly entering methadone maintenance treatment in Guangdong Province, China 2006-2013: a consecutive cross sectional study. Liu Y; Liu Y; Zou X; Chen W; Ling L BMJ Open; 2017 Jul; 7(7):e015524. PubMed ID: 28710214 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]